Clinical Trials Logo
  1. Home
  2. Intestinal Diseases
  3. NCT06201559

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

Intestinal Diseases Clinical Trial

Official title:
An Open Label, Balanced, Randomized, Two-Treatment, Four-Period, Two-Sequence, Single Oral Dose, Full Replicate Crossover, Bioequivalence Study of Albendazole Tablets IP 400 mg of Biddle Sawyer Limited (GSK Group Company) With Albendazole Tablets 400 mg of Glaxo SmithKline Consumer Healthcare, South Africa (PTY) Ltd in Healthy, Adult Participants Under Fed Condition

Clinical Trial Summary

The goal of this study is to compare two formulations of Albendazole of the same dose in healthy adult participants. Researchers will compare the extent and rate to which the drug is absorbed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06201559
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date August 21, 2023
Completion date September 12, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03032861 - The Prebiotic Effect of Daily Intake of Orange Juice Affects the Bioavailability of Flavanones? N/A
Recruiting NCT02295254 - Microbiome Changes in Travelers to Tropical Destinations N/A
Completed NCT02246647 - Biomarkers for Intestinal Permeability in Patients With Constipation
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Completed NCT01872286 - Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2 N/A
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02445365 - Remote Ischemic Conditioning in Patients With Ulcerative Colitis N/A
Recruiting NCT04949282 - Spanish Series of Patients Treated With the Radionuclide Lutetium177
Active, not recruiting NCT01995942 - Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
Completed NCT02647866 - Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis Phase 2
Completed NCT02693782 - Fabulous Fibre Study - Effect of Wheat Bran Extract on Gut and General Health in Healthy Aging Subjects (FFS) N/A
Not yet recruiting NCT02806206 - Prucalopride Prior to Small Bowel Capsule Endoscopy Phase 4
Completed NCT02831556 - Point of Care 3D Ultrasound for Various Applications: A Pilot Study
Terminated NCT04102163 - Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment
Terminated NCT02550860 - Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function Phase 3
Recruiting NCT02044952 - Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission Phase 2/Phase 3
Completed NCT02227602 - Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease N/A
Active, not recruiting NCT01028898 - Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome N/A